Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2019.1847
Abstract: Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months. Objective To determine whether adding… read more here.
Keywords: pfs; egfr mutant; trial; erlotinib ... See more keywords
Overcoming EGFR-Mediated Dendritic Cell Dysfunction to Enhance Anti-tumor Immunity in EGFR-Mutant NSCLC by Precisely Targeting CD73 With pH-responsive Nanocarriers.
Sign Up to like & getrecommendations! Published in 2025 at "Advanced science"
DOI: 10.1002/advs.202513182
Abstract: EGFR mutations remain a major challenge in immunotherapy for non‐small cell lung cancer (NSCLC), with poor responses to immune checkpoint inhibitors driven by mechanisms associated with EGFR mutation‐mediated tumor microenvironment (TME) modulation. This study reveals… read more here.
Keywords: mutant nsclc; dendritic cell; tumor; cell ... See more keywords
The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4543
Abstract: Epidermal growth factor receptor (EGFR) mutations were frequently found with concomitant genetic alterations in lung adenocarcinoma (LUAD). This study aimed to investigate the profile of concomitant alterations of EGFR‐mutant LUAD ≤3 cm in size and… read more here.
Keywords: lung adenocarcinoma; egfr mutant; molecular characteristics; characteristics resected ... See more keywords
Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR‐mutant nonsmall cell lung cancer with brain metastasis
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Cancer"
DOI: 10.1002/ijc.33904
Abstract: Osimertinib, as a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed more potent efficacy against brain metastasis (BM) in untreated EGFR‐mutant nonsmall cell lung cancer (NSCLC) in the FLAURA study. However, the… read more here.
Keywords: egfr; untreated egfr; egfr mutant; survival benefit ... See more keywords
Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-024-05618-4
Abstract: Purpose Immune checkpoint inhibitors (ICIs) are ineffective against epidermal growth factor receptor ( EGFR )-mutant non-small cell lung cancer (NSCLC). This study aimed to investigate the clinical characteristics of patients who were treated or not… read more here.
Keywords: cancer; lung; lung cancer; group ... See more keywords
Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study
Sign Up to like & getrecommendations! Published in 2025 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-025-02696-3
Abstract: We previously showed the 2-year OS rate, the primary endpoint, of 90% in a phase II trial of gefitinib induction followed by chemoradiotherapy (CRT) in unresectable, stage III, EGFR-mutant, non-small-cell lung cancer (NSCLC). However, neither… read more here.
Keywords: stage iii; year; gefitinib induction; egfr mutant ... See more keywords
Angiotensin-converting enzyme 2 is a potential therapeutic target for EGFR-mutant lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Biochemical and Biophysical Research Communications"
DOI: 10.1016/j.bbrc.2017.04.102
Abstract: Abstract EGFR-mutant lung adenocarcinomas contain a subpopulation of cells that have undergone epithelial-to-mesenchymal transition and can grow independently of EGFR. To kill these cancer cells, we need a novel therapeutic approach other than EGFR inhibitors.… read more here.
Keywords: lung adenocarcinoma; egfr; egfr mutant; mutant lung ... See more keywords
USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer letters"
DOI: 10.1016/j.canlet.2018.07.002
Abstract: As a newly discovered deubiquitinating enzyme, ubiquitin-specific protease 22 (USP22) is predictive of therapeutic outcomes in individual cancer patients. However, its clinical effects on malignancy and its roles in conferring resistance to EGFR-TKIs (epidermal growth… read more here.
Keywords: egfr; egfr mutant; resistance egfr; egfr tkis ... See more keywords
EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of cancer"
DOI: 10.1016/j.ejca.2019.08.021
Abstract: INTRODUCTION Previous studies suggested that epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKIs) plus bevacizumab could significantly prolong progression-free survival (PFS) than EGFR-TKI alone as first-line setting for patients with EGFR-mutant non-small-cell lung cancer (NSCLC).… read more here.
Keywords: egfr mutant; egfr tkis; tkis plus; patients egfr ... See more keywords
Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells.
Sign Up to like & getrecommendations! Published in 2019 at "International journal of pharmaceutics"
DOI: 10.1016/j.ijpharm.2019.118762
Abstract: Extracellular vesicles (exosomes, EVs) are cell membrane particles (30-200 nm) secreted by virtually all cells. During intercellular communication in the body, secreted EVs play crucial roles by carrying functional biomolecules (e.g., microRNAs and enzymes) into… read more here.
Keywords: gefitinib treatment; egfr mutant; cancer; cell ... See more keywords
A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.08.2028
Abstract: Introduction: Histologic transformation from NSCLC to SCLC is a mechanism of resistance in EGFR‐mutant tumors but is also occasionally observed in nonmutated NSCLC. Methods: We performed a multicenter retrospective collection of cases presenting between 2005… read more here.
Keywords: nsclc sclc; mutant group; egfr mutant; transformation ... See more keywords